Executive interview – Heidelberg Pharma at EKF 2019

Published on 6 December 2019

In this interview, Dr Jan Schmidt-Brand, CEO of Heidelberg Pharma, provides an overview of the company and what differentiates its ATAC products from other ADC or CAR-Ts on the market. He also shares the company’s key partnerships and pipeline overview, the upcoming catalysts investors should pay attention to, and how the company is funded.

Share this with friends and colleagues